$CRVS

Corvus Pharmaceuticals (CRVS) began a Phase 1b trial for soquelitinib to treat hidradenitis suppurativa, enrolling up to 25 patients. The trial will assess safety, efficacy, and biomarkers. Soquelitinib is also in trials for PTCL, atopic dermatitis, and ALPS, with a planned asthma trial. Hidradenitis suppurativa is a chronic inflammatory skin condition.

Corvus Pharmaceuticals (CRVS) reported on its Q2 2026 earnings call that soquelitinib, its oral ITK inhibitor, is being tested in five diseases. In a Phase 1 atopic dermatitis cohort, 75% on 200 mg twice daily reached EASI-75 at 8 weeks vs 20% placebo. Corvus said it has $215M cash and expects Phase 2 SEERA-1 results after early 2027. R&D rose to $16M and net loss to $18M.

Corvus Pharmaceuticals (CRVS) reported Q2 2026 cash and marketable securities of $215.2 million as of June 30, 2026, including $189.4 million from a January follow-on offering. Net loss was $18.0 million versus $8.0 million a year earlier. Management said cash runway funds operations into Q2 2028 and outlined Phase III PTCL and Phase II atopic dermatitis timelines for soquelitinib.

Siemens Energy was appointed to operate Guyana’s 300 MW gas-to-energy combined-cycle plant, with operations expected in early 2027, drawing gas from ExxonMobil’s Stabroek Block. Corvus Energy will supply 40 MWh battery systems for four BC Ferries hybrid vessels. Eco Wave Power reported H1 2026 operating expenses down 9%.

Corvus Pharmaceuticals (NASDAQ:CRVS) said an interim futility analysis for its PTCL Phase III trial is expected in Q1 2027, with an independent committee deciding whether to continue. Final Phase III PTCL data are still expected in late 2027. For atopic dermatitis, soquelitinib Phase I results showed EASI-75 of 75% vs 20% placebo; SIERRA-1 enrollment ends early 2027 with top-line data in Q3 2027.

Corvus Pharmaceuticals, Inc. (CRVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track Soquelitinib’s pote

Corvus Pharmaceuticals, Inc. (CRVS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Corvus Pharmaceuticals, Inc._July 21, 2026 0001626971 false 0001626971 2026-07-21 2026-07-21 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (

Corvus Pharmaceuticals said director David Scott Moore bought 21,700 common shares on June 11, 2026 via option exercise, according to a June 15 SEC Form 4. The weighted average purchase price was $11.53, with a $11.60 close price. Moore also holds 15,000 options at $11.60 that won’t vest until about a year later.

Moore David Scott purchased 21,700 shares of Corvus Pharmaceuticals, Inc. (CRVS) at $11.53 ($0.25M total) on 2026-06-11.

Corvus Pharmaceuticals, Inc. (CRVS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001626971 0001626971 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor